Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 7/20 | 0.42 |
| ▸ | CNR1 | P21554 | 6/20 | 0.42 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4678614 | 0.83 | CNR1 (0.44) | GABRA5CNR2CNR1 | |
| SCHEMBL5483536 | 0.81 | CNR1 (0.41) | CNR2CNR1NPC1RAB9A | |
| SCHEMBL4680498 | 0.81 | HTT (0.48) | CNR2CNR1 | |
| SCHEMBL4677223 | 0.80 | CNR1 (0.44) | GABRA5CNR2CNR1NPC1RAB9A | |
| SCHEMBL5754645 | 0.80 | GABRA5 (0.43) | GABRA5CNR2CNR1 | |
| SCHEMBL5483533 | 0.80 | CNR2 (0.46) | CNR2CNR1KMT2ANPC1RAB9A | |
| SCHEMBL4684369 | 0.79 | CNR1 (0.53) | CNR2CNR1 | |
| SCHEMBL5463864 | 0.78 | PHGDH (0.45) | — | |
| SCHEMBL5452834 | 0.78 | CNR1 (0.39) | CNR2CNR1 | |
| SCHEMBL4681440 | 0.76 | CNR1 (0.56) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093505-A1 | 2,3-Substituted 5,6-diaryl-pyrazine derivatives as cb1 modulators | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093505-A1 | 2,3-Substituted 5,6-diaryl-pyrazine derivatives as cb1 modulators | CNR2, CNR1, HTR2C | GABRA5 71/4885CNR2 1/4885CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.